Clinical Trial Search

Primary: Change From Baseline to Primary Endpoint in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) — -15.6; 3.3 score on a scale

Primary: Response Rate — 0 percentage of participants

Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscore Over 12 Weeks — -29.9; -27.0 score on a scale — p=0.5453

Primary: Baseline CAPS-5 Total Severity Score — 36.6; 36.8; 38.0; 37.3 score on a scale

Primary: Number of Patients With Dose-Limiting Toxicities (Phase I) — 1; 1 Participants

Primary: Overall Survival (OS) of Subjects Treated With Investigational Medicinal Product (IMP) (1 Year) — 100; 100; 100; 100 percentage of participants

Primary: Objective Response (Complete Response (CR)+Partial Response (PR) of Cabozantinib in Patients With Soft Tissue Sarcomas — 11.1 percentage of particpants

Primary: Ocular Itching — 0.508; 0.139; 2.485; 2.535 score on a scale — p=0.0882

Primary: Mean Change From Baseline (Average) in Alanine Aminotransferase (ALT) at Week 12 — -13.85; -23.76; -26.14 units per liter (U/L) — p=0.0495

Primary: Timely Initiation of Corticosteroids and Implementation of Biomarker-titrated Corticosteroid Dosing — 20; 19 Participants

Primary: Major Pathologic Response Rate (MPR) — 14; 3; 3; 10 Participants

Primary: Objective Response Rate — 25.8 percentage of participants

Primary: Median Survival — 11.8 months

Primary: 2-month Response Rate — 25 percentage of participants

Primary: Percent of Total Doses of Defibrotide That Were Missed [Feasibility] — 0.7 percentage of missed doses